NLRP12 Antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | P59046 |
Other Accession | NP_653288 |
Reactivity | Human |
Predicted | Human, Rat, Pig, Bovine, Dog |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 116kDa |
Gene ID | 91662 |
---|---|
Alias Symbol | NLRP12, NALP12, PYPAF7, RNO, |
Other Names | NACHT, LRR and PYD domains-containing protein 12, Monarch-1, PYRIN-containing APAF1-like protein 7, Regulated by nitric oxide, NLRP12, NALP12, PYPAF7, RNO |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 &mu, l of distilled water. Final Anti-NLRP12 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles. |
Precautions | NLRP12 Antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | NLRP12 |
---|---|
Synonyms | NALP12, PYPAF7, RNO |
Function | Plays an essential role as an potent mitigator of inflammation (PubMed:30559449). Primarily expressed in dendritic cells and macrophages, inhibits both canonical and non-canonical NF-kappa-B and ERK activation pathways (PubMed:15489334, PubMed:17947705). Functions as a negative regulator of NOD2 by targeting it to degradation via the proteasome pathway (PubMed:30559449). In turn, promotes bacterial tolerance (PubMed:30559449). Inhibits also the RIGI- mediated immune signaling against RNA viruses by reducing the E3 ubiquitin ligase TRIM25-mediated 'Lys-63'-linked RIGI activation but enhancing the E3 ubiquitin ligase RNF125-mediated 'Lys-48'-linked RIGI degradation (PubMed:30902577). Acts also as a negative regulator of inflammatory response to mitigate obesity and obesity-associated diseases in adipose tissue (By similarity). |
Cellular Location | Cytoplasm. |
Tissue Location | Detected only in peripheral blood leukocytes, predominantly in eosinophils and granulocytes, and at lower levels in monocytes. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Wang L.,et al.J. Biol. Chem. 277:29874-29880(2002).
Tschopp J.,et al.Nat. Rev. Mol. Cell Biol. 4:95-104(2003).
Williams K.L.,et al.Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
Shami P.J.,et al.Br. J. Haematol. 112:138-147(2001).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.